REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md. , Nov. 23, 2020 /PRNewswire/ —  REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ®  Technology Platform, today announced it will present at the following

No Comments

Comments are closed.